TIPP[psi], a highly selective delta ligand

Radiosynthesis and in vivo evaluation of the pseudopeptide delta-opioid antagonist [(125)I]ITIPP(psi)

The radioiodinated tetrapeptide delta-opioid antagonist [(125)I]ITIPP(psi) [H-Tyr(3'I)-Ticpsi[CH2NH]Phe-Phe-OH] (Ki(delta) = 2.08 nM; Ki(micro)/Ki(delta) = 1280) has been synthesized and evaluated as a potential lung tumour imaging agent. [(125)I]ITIPP(psi) was obtained, via electrophilic iodination, in 46% yield (>44,000 MBq/micromol) from the parent TIPP(psi). The biodistribution of [(125)I]ITIPP(psi) in nu/nu mice bearing SCLC-SW210.5 xenographs revealed good uptake and prolonged retention of radioactivity in organs known to possess delta-opioid receptors. Metabolite analysis showed that [(125)I]ITIPP(psi) was largely unmetabolized at 25 min PI and blocking studies showed significant reduction of uptake of the tracer in the brain, liver, intestine and tumor indicating that the iodinated tetrapeptide binds to delta opioid receptors in vivo.

The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists

The discovery of the prototype delta opioid antagonists TIPP (H-Tyr-Tic-Phe-Phe-OH) and TIP (H-Tyr-Tic-Phe-OH) in 1992 was followed by extensive structure-activity relationship studies, leading to the development of analogues that are of interest as pharmacological tools or as potential therapeutic agents. Stable TIPP-derived delta opioid antagonists with subnanomolar delta receptor binding affinity and extraordinary delta receptor selectivity include TIPP[Psi] (H-Tyr-TicPsi[CH(2)NH]Phe-Phe-OH] and TICP[Psi] (H-Tyr-TicPsi[CH(2)NH]Cha-Phe-OH); Cha: cyclohexylalanine), which are widely used in opioid research. Theoretical conformational analyses in conjunction with the pharmacological characterization of conformationally constrained TIPP analogues led to a definitive model of the receptor-bound conformation of H-Tyr-Tic-(Phe-Phe)-OH-related delta opioid antagonists, which is characterized by all-trans peptide bonds. Further structure-activity studies revealed that the delta antagonist vs delta agonist behavior of TIP(P)-derived compounds depended on very subtle structural differences in diverse locations of the molecule and suggested a delta receptor model involving a number of different inactive receptor conformations. A further outcome of these studies was the identification of a new class of potent and very selective dipeptide delta agonists of the general formula H-Tyr-Tic-NH-X (X = arylalkyl), which are of interest for drug development because of their low molecular weight and lipophilic character. Most interestingly, TIPP analogues containing a C-terminal carboxamide group displayed a mixed mu agonist/delta antagonist profile, and thus were expected to be analgesics with a low propensity to produce tolerance and physical dependence. This turned out to be the case with the TIPP-derived mu agonist/delta antagonist DIPP-NH(2)[Psi] (H-Dmt-TicPsi[CH(2)NH]Phe-Phe-NH(2)); Dmt: 2',6'- dimethyltyrosine).

Subtleties of structure-agonist versus antagonist relationships of opioid peptides and peptidomimetics

The development of novel delta opioid antagonists and delta opioid agonists structurally derived from the prototype delta antagonist TIPP (H-Tyr-Tic-Phe-Phe-OH), is reviewed. Both delta antagonists and delta agonists with extraordinary potency and unprecedented delta receptor selectivity were discovered. Some of them are already widely used as pharmacological tools and are also of interest as potential therapeutic agents for use in analgesia. The results of the performed structure-activity studies revealed that the delta antagonist versus delta agonist behavior of this class of compounds depended on very subtle structural differences in diverse locations of the molecule. These observations can be best explained with a receptor model involving a number of different inactive and active receptor conformations.

Spinal mu-, delta- and kappa-opioid receptors mediate intense stimulation-elicited inhibition of a nociceptive reflex in the rat

Intense electrical stimulation of meridian points in the rat inhibits the nociceptive tail withdrawal reflex. The objective of the present study was to determine whether spinal opioid receptors mediate this inhibition. Electrical stimulation was applied with 2 ms square pulses, at 4 Hz for 20 min at 20 times the threshold, to previously defined meridian points in the hindlimb. Threshold was the minimum current required to elicit muscle twitch. In lightly anaesthetized intact rats (n = 8) stimulation inhibited tail withdrawal during and for greater than one hour after the end of stimulation. In unanaesthetized spinal rats (n = 12) this inhibition was less and the post-stimulation effect lasted for 15 min. In control anaesthetized intact (n = 28) and unanaesthetized spinal rats (n = 14) placement of electrodes without stimulation had no effect. In spinal rats, preadministration of naloxone (25 mg/kg, i.p.) blocked the evoked inhibition (n = 11). In intact animals both naloxone (n = 8) and the mu-opioid receptor antagonist, beta-funaltrexamine (10 nmol; n = 9), given via a chronic intrathecal catheter, attenuated inhibitions during and after the end of stimulation by 50-60%. The delta-opioid receptor antagonist H-Tyr-tic psi[CH2NH]Phe-Phe-OH (TIPP[psi]; 10 nmol; n = 7) and the kappa-opioid receptor antagonist nor-binaltorphimine (10 nmol; n = 13) given by lumbar puncture attenuated the inhibition during the stimulation by 30% and 56%, respectively; both antagonists blocked the post-stimulation effect and even facilitated the withdrawal. The data suggest that spinal mu-, delta- and kappa-opioid receptors each contribute to the evoked inhibition.

Comparative analysis of various proposed models of the receptor-bound conformation of H-Tyr-Tic-Phe-OH related delta-opioid antagonists

A molecular mechanics study (grid search and energy minimization) was performed with six delta opioid peptide antagonists containing a tetrahydroisoquinoline-3-carboxylic acid (Tic) residue in the 2-position of the peptide sequence. Compounds examined were the highly potent and selective TIP(P) peptides H-Tyr-Tic-Phe-OH (TIP), H-Tyr-Tic psi[CH2-NH]Phe-OH (TIP[psi]), H-Tyr-Tic-Phe-Phe-OH (TIPP), and H-Tyr-Tic psi[CH2-NH]Phe-Phe-OH (TIPP[psi]), and the weakly active analogues H-Tyr-Tic-NH2 and H-Tyr-Tic-Ala-OH. Low energy conformers of the peptides were examined for their compatibility with three proposed models of the delta receptor-bound conformation. Model 1, based on spatial overlap of the Tyr1 and Phe3 aromatic rings and N-terminal amino group of the peptides with the corresponding aromatic rings and nitrogen atom of the nonpeptide delta-antagonist naltrindole, was ruled out because of the demonstrated importance of the Tic2 aromatic ring for delta antagonism and because of the somewhat elevated energies of the conformers consistent with this model. Models of the receptor-bound conformation based on superimposition of the Tyr1 and Tic2 aromatic rings and N-terminal amino group of the peptides with the corresponding moieties in naltrindole included an all-trans peptide bond conformer [model 2, proposed by B.C. Wilkes and P.W. Schiller (1994) Biopolymers, Vol. 34, pp. 1213-1219] and a conformer with a cis peptide bond between the Tyr1 and Tic2 residues (model 3, originally proposed by P.A. Temussi et al. [(1994) Biochemical and Biophysical Research Communications, Vol. 198, pp. 933-939]. For all six peptides low energy conformers consistent with both model 2 and model 3 were identified; however, peptide conformers corresponding to model 2 showed better coplanarity of the Tyr1 aromatic ring and the phenol ring in naltrindole than peptide conformers corresponding to model 3. Both models remain plausible candidate structures for the receptor-bound conformation of delta antagonists of the TIP(P) class. TIP(P) analogues containing additional conformational constraints need to be developed in order to arrive at a unique model.